Abstract
EFFICACY OF CDK4/6 INHIBITOR IN TREATMENT OF METASTATIC BREAST CANCER AND COLON CANCER

J. Raycheva, M.D.*1 and M. Taushanova-Hadjieva M.D. Ph.D2

ABSTRACT

Background: Efficacy of CDK4/6 inhibitors in treatment of metastatic breast cancer and colon cancer. Case report: A 52-y.o. woman was diagnosed with an invasive left-sided ductal breast cancer, G3 - T2N0M0; ER (3+), PR (+), HER2 (-), Ki67-11%. She underwent a radical mastectomy, followed by adjuvant chemotherapy and hormone treatment with Tamoxifen. A year later she was diagnosed with a colorectal cancer-low grade, G1; adenocarcinoma - T3N1M1 with liver metastases. After a biopsy, which revealed that the metastases are coming from the breast (ER+/HER 2(-) Breast cancer - (GATA (3+)), she was restaged as T3N1M0. The patient started treatment with Ribociclib 600mg/d + Letrozole 2,5mg/d with a complete response of the disease after three months of treatment. Due to G3 neutropenia, the dose was adjusted to 400 mg/d. Last restaging: July 2019 – stable disease and a good quality of life. This case approves that the CDK 4/6 inhibitors are able to manage visceral metastases and to provide long-term survival without worsening the quality of life. Conclusion: Her disease is successfully managed with CDK4/6 inhibitor together with hormonal therapy, which proves the effect of the CDK 4/6 inhibitors in treatment not only to breast cancer. Six months after there are no signs of relapse of the colon cancer. Despite the stage of the second cancer – T3N1M0, the patient did not undergo adjuvant treatment for the colon cancer.

Keywords: Metastatic breast cancer; colon cancer; hormone therapy; efficacy; safety profile.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tanima Debnath Sarkar

Download Article : Click here

News & Updation

  • EJBPS: OCTOBER ISSUE PUBLISHED

    OCTOBER 2021 Issue has been successfully launched on 1 October 2021

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT